10月28日，药明康德发布2024年三季报。与二季度趋势保持一致，药明康德三季度继续保持了环比超过10%的增长，单季度营收再次站在百亿之上。在稳健的业绩之外，更加值得注意的是，作为受到拟议《生物安全法案》寻求立法的第三个季度，三季度末药明康德在手订单 ...

Patritumab deruxtecan starts phase 3 Daiichi Sankyo meanwhile has started a phase 3 trial of another ADC – patritumab deruxtecan – comparing the drug to chemotherapy as a second-line therapy ...

第一三共公司和默沙东公司12月22日宣布，美国食品药品监督管理局（FDA）已受理patritumab deruxtecan的生物制品许可申请（BLA）并给予优先审评 ...

Daiichi Sankyo & AstraZeneca’s Enhertu receives 2024 Prix Galien USA Award for Best Biotechnology Product: Tokyo Monday, November 11, 2024, 09:00 Hrs [IST] Daiichi Sankyo and As ...

其中有两个例子市场讨论最多。 一个是默沙东与第一三共的重磅ADC药物Patritumab Deruxtecan，用于非小细胞肺癌（NSCLC）治疗，在去年底拿到优先审批 ...

MSD and Daiichi Sankyo's patritumab deruxtecan hit its main objective in a phase 3 lung cancer study that reinforces its potential as a new treatment option for patients after first-line tr The ...

The first patients have been dosed in three global, randomized phase 3 trials evaluating the efficacy and safety of datopotamab deruxtecan (Dato-DXd)- ...

导 ...

而在今年9月，默沙东和第一三共宣布，patritumab deruxtecan（HER3-DXd）治疗既往接受过EGFR-TKI治疗的局部晚期或转移性EGFR突变非小细胞肺癌（NSCLC ...

Patritumab deruxtecan (HER3-DXd), a HER3 directed ADC, ifinatamab deruxtecan (I-DXd), a B7-H3 directed ADC, and raludotatug deruxtecan (R-DXd), a CDH6 directed ADC, are being jointly developed and ...

Medscape Medical News, May 19, 2023 ESMO Breast Cancer 2023 Patritumab Deruxtecan Shows Promise for Breast Cancer A single dose of patritumab deruxtecan provoked a response in nearly one third of ...